News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alkermes (ALKS) Says Johnson & Johnson (JNJ) Will Not Pursue Further Development of Four-week Risperidone



8/27/2009 6:52:25 AM

Bookmark and Share

Reuters -- Units of Johnson & Johnson have decided not to pursue further development of a four-week long-acting version of antipsychotic drug risperidone, Alkermes Inc said in a regulatory filing on Wednesday.

Read at Reuters
Read at Forbes


comments powered by Disqus
Reuters
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES